Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium

Area of Science:

• Oncology
• Immunology
• Microbiology

Background:

• Conventional chemotherapies exhibit limitations such as lack of selectivity, toxicity to normal tissues, multidrug resistance, and tumor relapse.
• Immunotherapies represent a significant advancement in anticancer research, with bacteria-mediated cancer therapy emerging as a highly promising strategy.
• Attenuated Salmonella possess inherent tumor-targeting capabilities, making them suitable for delivering immunostimulatory agents to solid cancers.

Purpose of the Study:

• To review recent advancements in Salmonella-mediated cancer immunotherapy.
• To summarize the mechanisms underlying Salmonella-based cancer therapies.
• To highlight the potential of bacteria as vectors for cancer treatment.

Main Methods:

• Literature review of recent studies on Salmonella-mediated cancer immunotherapy.
• Analysis of the mechanisms by which attenuated Salmonella target cancer cells.
• Evaluation of the immunogenicity and in vivo anticancer immune response induced by Salmonella.

Main Results:

• Attenuated Salmonella demonstrate specific targeting of various solid tumors.
• These bacteria possess native immunogenicity, effectively stimulating anticancer immunity in vivo.
• Salmonella serve as effective vectors for delivering and expressing immunostimulators within the tumor microenvironment.

Conclusions:

• Salmonella-mediated cancer immunotherapy is a rapidly advancing field with significant therapeutic potential.
• The unique properties of attenuated Salmonella offer advantages over conventional cancer treatments.
• Further research into Salmonella-based strategies could lead to novel and effective cancer therapies.